ARSTAT Inc. Patent applications |
Patent application number | Title | Published |
20140296193 | MULTIPHASIC CONTRACEPTIVE REGIMEN FOR ORAL COMBINATION DRUG FORMULATION OF PROGESTIN AND ESTROGEN - A method of contraception in a female is provided. The method includes administering to the female daily for a first number of successive days an oral combination drug formulation of a progestin and an estrogen. The oral combination drug formulation is administered in a multiphasic dosing regimen comprising a second number of phases with duration of each phase is a third number of days. The doses of each of the progestin and estrogen in each subsequent phase of the regimen increase by a predefined dose increment as compared to the corresponding doses of the progestin and estrogen administered during immediately preceding phase of the regimen. The ratio of a daily dose of progestin to a daily dose of estrogen is maintained at a constant level during the entire dosing period. The first number of successive days period is followed by a fourth number of days without progestin and estrogen administration. | 10-02-2014 |
20140039054 | ORAL COMBINATION DRUG FORMULATION COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND A COMPLEMENTARY LOW DOSE OF TRANEXAMIC ACID FOR THE TREATMENT OF MENSTRUAL PAIN ACCOMPANIED WITH EXCESSIVE MENSTRUAL BLOOD LOSS - A method for relieving menstrual pain and reducing menstrual blood loss in a female is provided. The method comprises administering to the female an oral combination drug formulation comprising a first therapeutically effective dose of a non-steroidal anti-inflammatory drug (NSAID) and a second complementary low dose of tranexamic acid, wherein the NSAID is formulated to relieve the menstrual pain and to reduce a volume of menstrual blood loss of the female, wherein the dose of tranexamic acid ranges from 50 mg to 425 mg per oral combination drug formulation. | 02-06-2014 |
20140030313 | TREATMENT OF MENSTRUAL PAIN AND EXCESSIVE MENSTRUAL BLOOD LOSS BY INTRAVAGINAL ADMINISTRATION OF A LOW DOSE OF ANTIFIBRINOLYTIC OR HEMOSTATIC AGENT IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUG - A method for relieving menstrual pain and reducing menstrual blood loss in a female is provided. The method comprises administering intravaginally to the female a first therapeutically effective amount of a non-steroidal anti-inflammatory drug (NSAID) that relieves menstrual pain and a second therapeutically effective amount of an active agent that reduces menstrual blood loss, wherein the NSAID and the active agent are simultaneously administered by the same drug delivery device, wherein the active agent is any one of an antifibrinolytic agent and a hemostatic agent. | 01-30-2014 |
20140005157 | TREATMENT OF UTERINE FIBROIDS BY INTRAVAGINAL ADMINISTRATION OF A LOW DOSE OF SELECTIVE PROGESTERONE RECEPTOR MODULATOR (SPRM), ANTI-PROGESTIN, OR ANTI-PROGESTATIONAL | 01-02-2014 |
20140004171 | TREATMENT OF ENDOMETRIOSIS BY INTRAVAGINAL ADMINISTRATION OF A LOW DOSE OF A SELECTIVE PROGESTERONE RECEPTOR MODULATOR (SPRM), ANTI-PROGESTIN, OR ANTI-PROGESTATIONAL AGENT | 01-02-2014 |
20130345678 | TREATMENT OF EXCESSIVE MENSTRUAL BLOOD LOSS BY FEMININE SANITARY PRODUCTS MEDICATED WITH ANTIFIBRINOLYTIC OR HEMOSTATIC AGENT - A method, medicated feminine sanitary products and compositions for reducing menstrual blood loss in a female are provided. The method comprises delivering an active agent to the uterine cavity by administering intravaginally to the female a therapeutically effective amount of the active agent on a medicated feminine sanitary product during menstrual bleeding, wherein the medicated feminine sanitary product is routinely utilized to absorb the menstrual flow, wherein the active agent is incorporated in the medicated feminine sanitary product as a pharmaceutically acceptable composition, the active agent is any of an antifibrinolytic and a hemostatic agent. | 12-26-2013 |
20130337054 | TREATMENT OF EXCESSIVE MENSTRUAL BLOOD LOSS BY INTRAVAGINAL ADMINISTRATION OF LOW DOSES OF ANTIFIBRINOLYTIC OR HEMOSTATIC AGENT - A method and drug delivery device for reducing menstrual blood loss in a female are provided. The method comprises administering intravaginally to the female a therapeutically effective amount of an active agent on a delivery device directly to uterine cavity during a menstrual period, wherein the active agent is any one of an antifibrinolytic agent and a hemostatic agent. | 12-19-2013 |